candesartan + amlodipine + indapamide

**candesartan + amlodipine + indapamide** is a fixed-dose combination of three antihypertensive agents: - **Candesartan** is an angiotensin II receptor blocker (ARB) that selectively inhibits the angiotensin II type 1 receptor, leading to vasodilation and reduced blood pressure. - **Amlodipine** is a dihydropyridine calcium channel blocker that inhibits calcium influx in vascular smooth muscle, causing vasodilation and lowering blood pressure. - **Indapamide** is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting diuresis, reduced plasma volume, and reduced blood pressure. This triple combination is designed to provide additive antihypertensive effects through distinct mechanisms, useful for managing moderate to severe hypertension or cases that require multi-drug therapy. Clinical data supports similar combinations with improved blood pressure control and well-tolerated profiles[2][3][4]. As of September 2025, a fixed-dose triple combination with telmisartan (telmisartan + amlodipine + indapamide, known as GMRx2) is FDA-approved for hypertension[5], but no marketed product for the candesartan + amlodipine + indapamide combination is identified.

Other names

amlodipine/candesartan/indapamide